Efficacy and safety of once‐daily inhaled ciclesonide in adults with mild to moderate asthma: A double‐blind, placebo‐controlled study*

Abstract

Background and objective: Inhaled corticosteroids are recommended as first‐line therapy for the management of asthma, although side‐effects may limit their use. Ciclesonide, a novel pro‐drug inhaled corticosteroid, exerts potent and prolonged local anti‐inflammatory effects in the lungs, and is considered to have an improved safety and tolerability profile. The aim of this study was to evaluate the efficacy and safety of ciclesonide in adult patients with mild to moderate asthma. Methods: A placebo‐controlled, multicentre, randomized, double‐blind, parallel‐group study was conducted. During the 4‐week baseline period, patients were given 400 μg/day of beclomethasone dipropionate in a chlorofluorocarbon formulation. After the baseline period, 311 patients were given once‐daily 100, 200 or 400 μg of ciclesonide or placebo for an 8‐week treatment period without the use of a spacer. The primary efficacy variable was morning PEF. Results: Changes in the morning PEF (least squares mean) at the end of the study were 4.23 L/min (P < 0.001) in the 100 μg group, 3.75 L/min (P < 0.001) in the 200 μg group, −0.40 L/min (P < 0.001) in the 400 μg group, as compared with −24.95 L/min in the placebo group. In the ciclesonide groups, the PEF remained at the same level as the baseline period. No large differences were observed between the placebo group and the ciclesonide groups regarding safety. Conclusion: Once‐daily administration of ciclesonide at doses of 100, 200 or 400 μg was shown to be effective in adult patients with mild to moderate asthma. Ciclesonide is considered to have favourable safety profiles and be well tolerated.